Search

Author/Creator Belch, Andrew

1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022)

Authors:
Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar...
Journal:
Lancet
Issue:
Volume 9:Issue 6(2022)
Page Start:
e403
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice. Issue 1 (7th December 2018)

Authors:
Hulin, Cyrille; de la Rubia, Javier; Dimopoulos, Meletios A.; Terpos, Evangelos; Katodritou, Eirini; Hungria, Vania; De Samblanx, Hadewijch; Stoppa, Anne‐Marie; Aagesen, Jesper; Sargin, Deniz; Sioni, Anastasia; Belch, Andrew; Diels, Joris; Olie, Robert A.; Robinson, Don; Potamianou, Anna; van de ...
Journal:
Health science reports
Issue:
Volume 2:Issue 1(2019)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice. (5th September 2018)

Authors:
Terpos, Evangelos; Katodritou, Eirini; de la Rubia, Javier; Hungria, Vania; Hulin, Cyrille; Roussou, Maria; Delforge, Michel; Bries, Greet; Stoppa, Anne‐Marie; Aagesen, Jesper; Sargin, Deniz; Belch, Andrew; Ahlberg, Lucia; Diels, Joris; Olie, Robert A.; Robinson, Don; Spencer, Mike; Potamianou, A...
Journal:
European journal of haematology
Issue:
Volume 101:Number 4(2018)
Page Start:
556
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. (13th October 2020)

Authors:
Belch, Andrew; Bahlis, Nizar; White, Darrell; Cheung, Matthew; Chen, Christine; Shustik, Chaim; Song, Kevin; Tosikyan, Axel; Dispenzieri, Angela; Anderson, Kenneth; Brown, Diane; Robinson, Suzanne; Srinivasan, Shankar; Facon, Thierry
Journal:
Cancer medicine
Issue:
Volume 9:Number 23(2020)
Page Start:
8923
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Issue 6 (June 2020)

Authors:
Usmani, Saad Z; Nahi, Hareth; Plesner, Torben; Weiss, Brendan M; Bahlis, Nizar J; Belch, Andrew; Voorhees, Peter M; Laubach, Jacob P; van de Donk, Niels W C J; Ahmadi, Tahamtan; Uhlar, Clarissa M; Wang, Jianping; Feng, Huaibao; Qi, Ming; Richardson, Paul G; Lonial, Sagar
Journal:
Lancet
Issue:
Volume 7:Issue 6(2020)
Page Start:
e447
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Issue 10027 (9th April 2016)

Authors:
Lonial, Sagar; Weiss, Brendan M; Usmani, Saad Z; Singhal, Seema; Chari, Ajai; Bahlis, Nizar J; Belch, Andrew; Krishnan, Amrita; Vescio, Robert A; Mateos, Maria Victoria; Mazumder, Amitabha; Orlowski, Robert Z; Sutherland, Heather J; Bladé, Joan; Scott, Emma C; Oriol, Albert; Berdeja, Jesus; Ghari...
Journal:
Lancet
Issue:
Volume 387:Issue 10027(2016)
Page Start:
1551
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. Issue 4 (3rd April 2018)

Authors:
Drach, Johannes; Huang, Huiqiang; Samoilova, Olga; Belch, Andrew; Farber, Charles; Bosly, André; Novak, Jan; Zaucha, Jan; Dascalescu, Angela; Bunworasate, Udomsak; Masliak, Zvenyslava; Vilchevskaya, Kateryna; Robak, Tadeusz; Pei, Lixia; Rooney, Brendan; van de Velde, Helgi; Cavalli, Franco
Journal:
Leukemia & lymphoma
Issue:
Volume 59:Issue 4(2018)
Page Start:
896
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth. (5th July 2017)

Authors:
Dimopoulos, Meletios A.; Lonial, Sagar; White, Darrell; Moreau, Philippe; Palumbo, Antonio; San‐Miguel, Jesus; Shpilberg, Ofer; Anderson, Kenneth; Grosicki, Sebastian; Spicka, Ivan; Walter‐Croneck, Adam; Magen, Hila; Mateos, Maria‐Victoria; Belch, Andrew; Reece, Donna; Beksac, Meral; Bleickardt, ...
Journal:
British journal of haematology
Issue:
Volume 178:Number 6(2017)
Page Start:
896
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗